Anti-angiogenic Therapy Versus Dose-Dense Paclitaxel Therapy for Frontline Treatment of Epithelial Ovarian Cancer: Review of Phase III Randomized Clinical Trials

Current Oncology Reports

Volumn 16, Issue 11, 2014, Pages 1-8

  Slaughter, Katrina N ^a   Moore, Kathleen N ^a   Mannel, Robert S ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Anti angiogenesis; Dose dense; Gynecological cancer; Oncology; Ovarian cancer; Toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; TREBANANIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE DENSIFICATION; HUMAN; HYPERTENSION; NEUTROPENIA; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SENSORY NEUROPATHY; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; DISEASE FREE SURVIVAL; FEMALE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84920887162     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0412-2     Document Type: Review

References (36)

1. Siegal R, Ma J, Zou Z, Jemal A. Cancer Satistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Bailliere’s best practice and research. Clin Obstet Gynaecol. 2000;14:901–18.
3. Burger RA. Overview of antiangiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121:230–8.
4. Ferrara N. VEGF as a therapeutic target in ovarian cancer. Oncology. 2005;69 Suppl 3:11–6.
5. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–8.
6. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013;73:1649–57.
7. Singh M, Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol. 2012;30(7):648–57.
8. Randall LM, Burger RA, Nguyen H, Kong G, Bookman MA, Fleming GF, et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol Oncol. 2013;130 (1);e33–e34.
9. Perren T, Swart AM, Pfisterer J, Ledermann JA, Pujade-Laurain E, et al. A phase III trial of bevacizumab in ovarian cancer. New Engl J Med. 2011;365:2484–96.
10. Du Bois A, Floquet A, Weon Kim J, Rau J, Del Campo JM, Friedlander M, et al. Randomized double blind phase III trial of pazopanib versus placebo in women who have not progressed after first line chemotherapy for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol. 2013;31(No 18 suppl; Abstr LBA 5503)
11. GlaxoSmithKline (GSK) Regulatory update: Votrient (pazopanib) as maintenance therapy for advancaed ovarian cancer in the EU. http://www.gsk.com/en-gb/media/press-releases/2014/regulatory-update-votrient-pazopanib-as-maintenance-therapy-for-advaned-ovarian-cancer-in-the-eu/ Accessed 31 Mar 2014
12. Du Bois A, Kristensen G, Ray-Coquard I, Reub A, Pignata S, Colombo N, et al. AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J of Gynecol Cancer. 2013;23(8 Suppl 1):7–8
13. Ledermann JA, Perren TJ, Raja FA, Embleton A, Rustin GJS, Jayson G, et al. Randomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. European J of Cancer 2013;49(Suppl 3):Abract 10
14. A prospective, phase III, randomized, double blind placebo controlled trial evaluating adding trebananib to carboplatin and paclitaxel in the upfront treatment of patients with advanced stage ovarian cancer (NCT01493505). http://clinicaltrials.gov. Accessed 6 Jun 2014.
15. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. European J of Cancer 2013;49(suppl 3):Abstract 41
16. Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in firstline therapy of advance ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2014;32:1210–7.
17. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase III randomized trial. Lancet Oncol. 2013;14:236–43.
18. Norton L. Theoretical concepts and the merging role of taxanes in adjuvant therapy. Oncologist. 2001;6 Suppl 3:30–5.
19. Belotti D, Vergani V, Drudis T, Borsotti P, et al. The microtubule-affecting drug pacilitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–9.
20. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 2003;14:13–9.
21. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997;57:81–6.
22. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundgvist E, et al. consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIGOCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7–12.
23. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with tratuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642–9.
24. Sparano JA, Wang M, Martino S, Jones V, Perez EA, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–71.
25. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial. Lancet. 2013;14:1020–6.
26. Chan J, Brady M, Penson RT, Monk B, Boente M, Walker J, et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J of Gynecol Cancer 2013;23(8 suppl 1):9-10
27. Pignata S et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomized, multicenter, open-label, phase 3 trial. Lancet Oncol. 2013;15:396–405.
28. An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01654146). http://clinicaltrials.gov. Accessed 18 Jul 2014.
29. Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014;132(1):8–17.
30. Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Onc 32:5s,2014;(suppl; abstr 5502)
31. Winterhoff BJN, Kommoss S, Oberg AL, Wang C, Riska SM, Konecny GE, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol 32:5s, 2014;(suppl; abstr 5509)
32. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.
33. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419–25.
34. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.
35. Hertz DL, McLeod HL. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin Cancer Res. 2014;20:2530–40.
36. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New Engl J Med. 2011;365:2473–83.